狄诺塞麦医保能给报销吗？

Can medical insurance reimburse me? On May 23, 2019, the China National Medical Products Administration announced conditional approval of the import registration application for denosumab injection (denosumab). The drug will be used to treat adults and skeletally mature adolescent patients with unresectable giant cell tumors of bone or whose surgical resection may result in severe functional impairment. Denosumab has been on the market for a short time in the country and cannot yet be reimbursed through medical insurance.

Denosumab's mechanism of action: RANKL is a transmembrane or soluble protein that plays an important role in the formation, function, survival and cells responsible for bone resorption of osteoclasts, regulating the release of calcium from bone. Through RANKL stimulation, osteoclast activity is enhanced, mediating the occurrence of bone metastasis bone pathology in solid tumors. Denosumab can bind to the RANKL protein, preventing RANKL from binding to the receptor RANK expressed on the surface of osteoclasts, precursor cells, and osteoclast-like giant cells to activate subsequent malignant processes, thus exerting an anti-bone metastasis effect.

An international phase 3, randomized, double-blind, multicenter trial of denosumab compared with zoledronic acid for the prevention of skeletal-related events in adult patients with newly diagnosed multiple myeloma. In the study, a total of 1,718 patients (859 in each group) were randomly assigned to receive either subcutaneous denosumab 120 mg and intravenous placebo every four weeks or intravenous zoledronic acid 4 mg (adjusted for renal function) and subcutaneous placebo every four weeks.

The results showed that compared with zoledronic acid, the overall survival hazard ratio was 0.90. The hazard ratio for denosumab versus zoledronic acid for the exploratory endpoint of progression-free survival was 0.82. The median difference in progression-free survival between arms was 10.7 months. This study compared the safety and tolerability of denosumab with that of zoledronic acid. The most common adverse events (greater than or equal to 25%) were diarrhea and nausea.